Amgen receives EC approval to add OS data to BLINCYTO® (blinatumomab) label
Amgen announced that the EC has granted a full marketing authorization for BLINCYTO® (blinatumomab) based on the overall survival data from the Phase 3 TOWER study in adult patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
June 19, 2018